Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYNB2081 (97b076)
- Development stage
- Discontinued
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
SYNB2081 (SYN-GOUT) is an orally administered, non-systemically absorbed Synthetic Biotic developed by Synlogic in partnership with Ginkgo Bioworks for the treatment of gout. It is a genetically engineered strain of the probiotic bacterium *Escherichia coli* Nissle 1917 designed to express bacterial and fungal urate oxidase enzymes and overexpress a urate transporter. Within the gastrointestinal tract, SYNB2081 imports and metabolizes uric acid into 5-hydroxyisourate, which spontaneously degrades into the highly soluble and easily excreted metabolite allantoin. This localized consumption of uric acid in the gut leverages the enterorecirculation loop to lower systemic uric acid levels, offering a potential therapeutic option for gout, particularly in patients with compromised kidney function. Development of SYNB2081 was discontinued in February 2024 when Synlogic ceased operations following the failure of its lead Phase 3 program.
- Other names
- engineered Escherichia coli Nissle 1917
Beyond the preview
Go deeper on SYNB2081 (97b076).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYNB2081 (97b076).